Neuromuscular Rehabilitation for ACL Injury Prevention in Athletes
Trial Summary
What is the purpose of this trial?
The overall goal of this project is to reduce risk of second anterior cruciate ligament (ACL) injury in vulnerable populations (active athletes between 14 = 24 years old) through the identification of relative injury risk groups based on subject-specific movement patterns prior to second injury, as well as through the determination of effect for differential rehabilitation protocols following initial ACL reconstruction and prior to return to sport. As nearly one-third of athletes who have a primary ACL injury and return to sport will experience a secondary injury, results from the proposed work will allow us to prospectively identify high risk patients who are the most appropriate recipients of enhanced treatment, including targeted training, which may reduce the risk of second ACL injury. Secondary ACL injury has the potential to end athletic careers, promote the development of osteoarthritis, and have debilitating effects on quality of life. Hence, the information gathered in this investigation will offer ACL injured athletes the optimal potential to reduce or potentially prevent these negative health effects before they are initiated.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the treatment Neuromuscular Intervention for ACL injury prevention in athletes?
Is neuromuscular training safe for humans?
How is the neuromuscular intervention treatment different from other treatments for ACL injury prevention?
Neuromuscular intervention (NMT) is unique because it focuses on training the body's nervous and muscular systems to improve movement patterns and reduce the risk of ACL injuries, especially in athletes. Unlike other treatments that may focus on post-injury rehabilitation, NMT is preventive and aims to correct high-risk landing mechanics and enhance knee function before injuries occur.12589
Research Team
Aaron J Krych, MD
Principal Investigator
Mayo Clinic
Eligibility Criteria
This trial is for active athletes aged between 14 and 24 who have had their first ACL injury within the last 6 months. They should not have had previous knee surgeries, complex meniscus tears, or other recent injuries that required medical care. Participants must have been involved in sports requiring cutting, jumping, or pivoting for at least 50 hours a year.Inclusion Criteria
Exclusion Criteria
Timeline
Screening
Participants are screened for eligibility to participate in the trial
Treatment
Participants undergo different rehabilitation protocols including HOME, STAN, and TNMT over a six-week period
Follow-up
Participants are monitored for safety and effectiveness after treatment, including assessment of knee kinematics and kinetics
Treatment Details
Interventions
- Neuromuscular Intervention
Find a Clinic Near You
Who Is Running the Clinical Trial?
Mayo Clinic
Lead Sponsor
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
Collaborator